

TABLE 1 Baseline characteristics of women who returned for at least one follow-up visit after randomization to placebo or troglitazone

	Placebo group	Troglitazone group	P
<i>n</i>	122	144	
Clinical characteristics			
Age (years)	34.3 ±6.5	34.9 ± 6.6	0.52
Bmi (kg/m ²)	30.3 ±5.3	30.6 ± 6.1	0.63
Waist-to-hip circumference ratio	0.86 ±0.05	0.85 ± 0.06	0.19
Using hormonal contraceptives*	48%	3%	0.41
OGTT			
Fasting glucose (mg/dl)	98.1 ±9.1	98.7 ± 10.2	0.64
2-h glucose	154.0 ±24.0	154.4 ± 27.0	0.97
Total glucose area (mg/dl x min x 10 ⁻³)‡	18.7 ±2.0	18.9 ± 2.0	0.25
Impaired glucose tolerance §	72%	69%	0.66
Fasting insulin (µU/ml)	16.0 ±7.5	17.0 ± 10.8	0.82
Total insulin area (µU/ml min)‡	10,209 ±5536	9,902 ± 6543	0.55